The Medicines Company

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
Type
Public
HQ
Parsippany Troy Hills, US
Founded
1996
Size (employees)
410 (est)-33%
The Medicines Company was founded in 1996 and is headquartered in Parsippany-Troy Hills, US

The Medicines Company Office Locations

The Medicines Company has an office in Parsippany-Troy Hills
Parsippany Troy Hills, US (HQ)
8 Sylvan Way

The Medicines Company Data and Metrics

The Medicines Company Financial Metrics

The Medicines Company's revenue was reported to be $167.8 m in FY, 2016 which is a 46% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

167.8 m

Revenue growth (FY, 2015 - FY, 2016), %

(46%)

Net income (FY, 2016)

(119.2 m)

EBIT (FY, 2016)

(361.9 m)

Market capitalization (25-May-2017)

2.8 b

Closing share price (25-May-2017)

40

Cash (31-Dec-2016)

541.8 m
The Medicines Company's current market capitalization is $2.8 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

5.1 m1.3 m309 m167.8 m

Revenue growth, %

(75%)23670%(46%)

Operating expense total

581.5 m529.8 m

EBIT

(272.5 m)(361.9 m)

EBIT margin, %

(88%)(216%)

Interest expense

37.1 m44.5 m

Pre tax profit

(251.7 m)(119.3 m)

Income tax expense

(70 k)

Net Income

15.5 m(32.2 m)(352.7 m)(119.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

376.7 m370.7 m373.2 m541.8 m

Accounts Receivable

2 k

Inventories

12.6 m16 m20 m19.1 m

Current Assets

591.4 m657 m832.9 m654 m

Goodwill

257.7 m286.5 m289.4 m255.6 m

Total Assets

1.7 b1.9 b1.8 b1.7 b

Accounts Payable

26.9 m19.8 m36 m28.5 m

Current Liabilities

174.3 m403.8 m536.7 m244.6 m

Additional Paid-in Capital

992 m1 b1.2 b1.3 b

Retained Earnings

(44.9 m)(77.1 m)(429.9 m)(549 m)

Total Equity

731.8 m652 m

Financial Leverage

2.5 x2.6 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

15.3 m(32.3 m)(352.7 m)(119.2 m)

Depreciation and Amortization

32.2 m34.4 m34.8 m31 m

Accounts Receivable

(15 m)(55 m)103 m30.1 m

Inventories

39 k(3.6 m)(5.3 m)569 k

Accounts Payable

(1.3 m)(6.9 m)16.4 m(7.4 m)

Cash From Operating Activities

91.4 m67.3 m(198 m)(323.3 m)

Cash From Investing Activities

(504.4 m)(84.8 m)(123.5 m)422 m

Cash From Financing Activities

271.5 m8.8 m324.8 m70.6 m

Interest Paid

4.4 m3.8 m8.8 m12.3 m

Income Taxes Paid

9.1 m1.4 m114 k36 k
Numbers are in $, USDY, 2016

Revenue/Employee

273.3 k

Financial Leverage

2.6 x

The Medicines Company Market Value History

The Medicines Company Online and Social Media Presence

The Medicines Company Company Life and Culture

You may also be interested in